Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar

التفاصيل البيبلوغرافية
العنوان: Multidisciplinary team intervention to reduce the nocebo effect when switching from the originator infliximab to a biosimilar
المؤلفون: Francis Berenbaum, Marie Antignac, Rose-Marie Poilverd, C. Beauvais, Sylvie Darthout, Régine Baratto, Juliette Petit, Nathalie Deparis, Sandra Desouches, Karine Louati
المساهمون: Service de rhumatologie [CHU Saint-Antoine], CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Pharmacie [CHU Saint Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Association Nationale de Défense contre l'Arthrite Rhumatoide (ANDAR), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
المصدر: RMD Open : Rheumatic & Musculoskeletal Diseases
RMD Open : Rheumatic & Musculoskeletal Diseases, EULAR ; BMJ, 2021, 7 (1), pp.e001396. ⟨10.1136/rmdopen-2020-001396⟩
RMD Open : Rheumatic & Musculoskeletal Diseases, BMJ, 2021, 7 (1), pp.e001396. ⟨10.1136/rmdopen-2020-001396⟩
RMD Open, Vol 7, Iss 1 (2021)
RMD Open
بيانات النشر: HAL CCSD, 2021.
سنة النشر: 2021
مصطلحات موضوعية: Ankylosing, medicine.medical_specialty, Immunology, Psychological intervention, Education, atient Care Team, Arthritis, Rheumatoid, 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Rheumatoid, Internal medicine, medicine, Humans, Immunology and Allergy, 030212 general & internal medicine, Nocebo Effect, Biosimilar Pharmaceuticals, Patient Care Team, 030203 arthritis & rheumatology, business.industry, Arthritis, Biosimilar, medicine.disease, Infliximab, 3. Good health, Discontinuation, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Rheumatoid arthritis, Cohort, Medicine, business, Historical Cohort, Spondylitis, medicine.drug
الوصف: ObjectivesTo evaluate an intervention to reduce the nocebo effect (NE) when switching from the originator infliximab (OI) to the infliximab biosimilar SB2 in chronic inflammatory rheumatic disease (CIRD).MethodsAn intervention was built with healthcare professionals (HPs) and a patient representative, based on a systematic review of interventions reducing the NE in musculoskeletal diseases and semi-directed questioning of five patients. Our strategy consisted of training HPs, switch information given by the nurses, a consistent vocabulary. All CIRD patients switched from OI to SB2 were included for the intervention. The primary outcome was the SB2 retention rate (RR) at 34 weeks. Secondary outcomes were the SB2 RR at 12 months, discontinuation rates due to a possible NE and comparison with a historical cohort of CIRD patients receiving the OI and 6 published European cohorts.Results45 patients were included from March 2018 (rheumatoid arthritis, n=17, spondylarthritis, n=28). After 34 weeks, the SB2 RR was 91.2%, similar to the historical cohort RR (p=0.41) but higher than the 3 European cohort RRs (pConclusionsA tailored communication with a prominent role of nurses reduced the NE in non-medical switches from the OI to SB2 as compared to published results. The RR was similar to the historical cohort RR. The methodology used to construct this intervention may help improve the outcomes of switches with upcoming biosimilars.
اللغة: English
تدمد: 2056-5933
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::116d0f0317f0717d40830e82ee93bd52Test
https://hal.sorbonne-universite.fr/hal-03123161/file/e001396.full.pdfTest
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....116d0f0317f0717d40830e82ee93bd52
قاعدة البيانات: OpenAIRE